Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 7/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6563345 | 0.83 | CYP2C19 (0.53) | GRIA4CYP2C19EPHX2NR1H4GRIA2 | |
| SCHEMBL6564976 | 0.81 | CYP2C19 (0.38) | GRIA4CYP2C19HDAC3HDAC1HDAC2 | |
| SCHEMBL6565067 | 0.80 | GRIA4 (0.42) | GRIA4EPHX2NR1H4GRIA2TRPV1 | |
| SCHEMBL13256290 | 0.79 | CYP2C19 (0.49) | GRIA4CYP2C19GRIA2 | |
| SCHEMBL13255837 | 0.79 | CYP2C19 (0.49) | GRIA4CYP2C19GRIA2 | |
| SCHEMBL5187414 | 0.78 | CYP2C19 (0.41) | GRIA4CYP2C19GRIA2 | |
| SCHEMBL14394435 | 0.77 | CYP2C19 (0.48) | GRIA4CYP2C19EPHX2NR1H4 | |
| SCHEMBL5188496 | 0.77 | CYP2C19 (0.48) | GRIA4CYP2C19 | |
| SCHEMBL5188470 | 0.76 | GRIA4 (0.48) | GRIA4CYP2C19EPHX2 | |
| SCHEMBL3703932 | 0.76 | CYP2C19 (0.47) | GRIA4CYP2C19EPHX2NR1H4GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1296945-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001096289-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | GRIA4 17/4885CYP2C19 2069/4885EPHX2 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.